Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patientskatie8288Jun 20, 20240 min read
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec(AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
Comments